Label vial upon first use
Self-administration of research peptides carries inherent risks including contamination, incorrect dosing, and unknown long-term effects
Insider Tip: BPC-157 should not be used by people with diagnosed or suspected cancer, as its potential to promote new blood vessel formation could cause cancer to grow or spread.19 Whos a candidate for BPC-157 peptide therapy
But the weight gain is not a direct result of the deficiency but rather an indirect result
USA 118 , e2021073118 (2021)
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
